News Sentiment

BNTC sentiment intelligence

Benitec Biopharma Ltd ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 46 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 13.42 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

75/100 classification confidence.

Company focus 37

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+1.5% over one week, +20.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

(BNTC) and the Role of Price-Sensitive Allocations

Market Reaction

Balanced read

57/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 75/100 classification
One-week reaction 1.5% Price digesting
Trend fit Trend active 20.0% over four weeks
Fair value 39.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 31
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 37
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 7
Stock Titan 5
Stock Traders Daily 4
TradingView 4
TradingKey 4
dars.gov.et 4
Finviz 2
www.marketscreener.com 2

Event Lens

What the news is about

Classified themes
Market update 19
Earnings 17
Guidance 6
Analyst action 2
Regulatory and legal 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 46
Stock Traders Daily Direct company coverage

(BNTC) and the Role of Price-Sensitive Allocations

This article provides an AI-generated analysis of Benitec Biopharma Inc. (NASDAQ: BNTC), highlighting strong near and mid-term sentiment but a weak long-term outlook. It details specific institutional trading strategies including position, momentum breakout, and risk hedging, alo

Tone
Negative 29/100
Event
Guidance
Published
11 Jul 2026 21:39
Source
Stock Traders Daily
TradingView Direct company coverage

Price to sales forward of Benitec Biopharma Inc. – NASDAQ:BNTC

This article provides financial data for Benitec Biopharma Inc. (NASDAQ: BNTC), specifically focusing on its price-to-sales forward metric. The content appears to be a stub or a section from a larger financial data platform like TradingView, showing the header for this specific m

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 04:09
Source
TradingView
Finviz Direct company coverage

BNTC - Benitec Biopharma Inc Latest SEC Filings

This article provides the latest SEC filings information for Benitec Biopharma Inc (BNTC) as of July 2, with detailed financial metrics, performance indicators, and company statistics. It includes data points such as market capitalization, income, sales, EPS, various ratios, insi

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 23:39
Source
Finviz
Investing.com Nigeria Direct company coverage

Form 4 Benitec Biopharma Ltd ADR For: 30 June By Investing.com

This article announces the filing of Form 4 for Benitec Biopharma Ltd ADR, pertaining to transactions made up to June 30. Form 4 is a document filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in their ownership of company stock. T

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 10:39
Source
Investing.com Nigeria
Stock Traders Daily Direct company coverage

Responsive Playbooks and the BNTC Inflection

This article analyzes Benitec Biopharma Inc. (NASDAQ: BNTC) using AI models to provide trading strategies and signal analysis. It highlights mixed sentiment, resistance testing, and an exceptional risk-reward short setup. The analysis includes position, momentum breakout, and ris

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 20:22
Source
Stock Traders Daily
Stock Titan Direct company coverage

Benitec Biopharma (NASDAQ: BNTC) director gifts 51,813 shares to donor-advised fund

Benitec Biopharma director J. Kevin Buchi reported a charitable stock gift of 51,813 shares to a donor-advised fund on June 29, 2026. This transaction was a non-market disposition at no stated price, intended for philanthropic purposes, and is not an indication of Buchi's view on

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 20:21
Source
Stock Titan
www.marketscreener.com Direct company coverage

Benitec Biopharma Inc.(NasdaqCM: BNTC) added to Russell 2000 Value Benchmark

Benitec Biopharma Inc. (NasdaqCM: BNTC) has been added to the Russell 2000 Value Benchmark. The company, a clinical-stage biotechnology firm, specializes in genetic medicines and is advancing a novel "Silence and Replace" gene therapy platform. This addition highlights its recogn

Tone
Positive 66/100
Event
Market update
Published
29 Jun 2026 15:10
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Microcap Value Benchmark Index

Benitec Biopharma Inc. (BNTC) has been added to the Russell Microcap Value Benchmark Index. This news follows a previous announcement that the company was also added to the Russell 2000 Value Benchmark Index. The biotechnology company, focused on genetic medicines, recently repor

Tone
Positive 66/100
Event
Market update
Published
29 Jun 2026 13:10
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Small Cap Comp Value Benchmark

Benitec Biopharma Inc. (NasdaqCM:BNTC) has been added to the Russell Small Cap Comp Value Benchmark, as reported on June 28, 2026. This indicates the company's inclusion in a significant small-cap index. The article also lists other recent inclusions in various Russell Value Benc

Tone
Positive 72/100
Event
Market update
Published
28 Jun 2026 22:10
Source
marketscreener.com
TradingView Direct company coverage

Benitec Biopharma Inc Actuals & Estimates (NASDAQ:BNTC)

This article provides an overview of Benitec Biopharma Inc. (NASDAQ:BNTC) stock performance, financial data, and analyst estimates. It details the company's current stock price, historical highs and lows, market capitalization, and upcoming earnings report. The piece also include

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 04:11
Source
TradingView
TradingView Direct company coverage

BNTC Forecast — Price Target — Prediction for 2027

The article provides a forecast and price target for Benitec Biopharma Inc. (BNTC) stock, including analyst opinions, historical performance, and key financial metrics. It details the current stock price, volatility, market capitalization, earnings, and revenue, along with the da

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 18:11
Source
TradingView
TradingKey Direct company coverage

Benitec Biopharma Inc (BNTC) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Benitec Biopharma Inc (BNTC), highlighting its current valuation score of 8.43, which ranks 135 out of 389 in the Biotechnology & Medical Research industry. The company's P/E ratio is noted as -13.33. The analysis also states that rel

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 03:09
Source
TradingKey
TradingKey Direct company coverage

Benitec Biopharma Inc (BNTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Benitec Biopharma Inc (BNTC), detailing its current price momentum score, support and resistance levels, and indicator and moving average signals. It notes that BNTC is trading between a resistance of 12.55 and support of 10.52, sugge

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 11:11
Source
TradingKey
TradingKey Direct company coverage

Benitec Biopharma Inc (BNTC) Institutional Confidence

Benitec Biopharma Inc (BNTC) currently holds an institutional shareholding score of 10.00, placing it first among 388 companies in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 96.50%, marking a significant quarter-over-quarter

Tone
Positive 61/100
Event
Market update
Published
18 Jun 2026 11:11
Source
TradingKey
TradingKey Direct company coverage

Benitec Biopharma Inc (BNTC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an in-depth look at Benitec Biopharma Inc's (BNTC) shareholder structure, detailing major individual and institutional holdings. It outlines the proportion of shares held by various shareholder types like hedge funds and investment advisors, and tracks insti

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:40
Source
TradingKey
Simply Wall Street Direct company coverage

Benitec Biopharma (Nasdaq:BNTC) - Stock Analysis

This article provides a stock analysis for Benitec Biopharma (BNTC), highlighting its position as a clinical-stage biotechnology company focused on genetic medicines, particularly its lead asset BB-301 for OPMD dysphagia. It notes the company's financial risks due to unprofitabil

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 03:39
Source
Simply Wall Street
GuruFocus Direct company coverage

Benitec Biopharma (BNTC) Faces Downgrade Amid Uncertainty

Guggenheim downgraded Benitec Biopharma (BNTC) from Buy to Neutral and ceased coverage due to uncertainties surrounding FDA guidance for its pivotal BB-301 study. Despite strong financial strength, the company faces significant challenges in profitability with a low GF Score of 3

Tone
Negative 27/100
Event
Guidance
Published
10 Jun 2026 15:09
Source
GuruFocus
Stock Traders Daily Direct company coverage

The Technical Signals Behind (BNTC) That Institutions Follow

This article provides a technical analysis of Benitec Biopharma Inc. (NASDAQ: BNTC) based on AI models, indicating weak sentiment across all horizons and suggesting a short bias. It outlines various trading strategies including position trading, momentum breakout, and risk hedgin

Tone
Negative 29/100
Event
Market update
Published
08 Jun 2026 18:02
Source
Stock Traders Daily
Stock Traders Daily Direct company coverage

Precision Trading with Benitec Biopharma Inc. (BNTC) Risk Zones

This article analyzes Benitec Biopharma Inc. (BNTC) using AI models to provide precise trading strategies. Key findings indicate strong near-term sentiment challenging persistent mid and long-term weakness, with a support test and exceptional risk-reward setup targeting a 17.8% g

Tone
Negative 42/100
Event
Market update
Published
30 May 2026 11:08
Source
Stock Traders Daily
Finviz Direct company coverage

BNTC - Benitec Biopharma Inc Stock Price and Quote

This article provides comprehensive financial data and news for Benitec Biopharma Inc. (BNTC). It details the company's stock performance, key financial metrics, recent analyst ratings, and a chronological list of news releases related to its operational updates and clinical tria

Tone
Positive 60/100
Event
Analyst action
Published
29 May 2026 21:10
Source
Finviz
Stock Titan Direct company coverage

Benitec Biopharma (NASDAQ: BNTC) adds director as CFO exits board role

Benitec Biopharma Inc. has appointed David Friedman as a Class III director to its board, effective May 22, 2026, granting him options to purchase 35,000 shares of common stock. Concurrently, CFO and Secretary Megan Boston resigned from the board as part of a governance review, b

Tone
Neutral 50/100
Event
Market update
Published
29 May 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Benitec Biopharma (BNTC) director option grant benefits Suvretta-managed funds

Benitec Biopharma director David Matthew Friedman was granted 35,000 stock options with an exercise price of $11.45 and an expiration date of May 26, 2036. These options are explicitly held for the benefit of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd., which

Tone
Neutral 50/100
Event
Market update
Published
29 May 2026 02:09
Source
Stock Titan
The Globe and Mail Direct company coverage

Benitec Biopharma Announces Board Changes and New Director

Benitec Biopharma recently announced board changes, including the appointment of David Friedman as a Class III director and the resignation of Megan Boston, who will continue as CFO. Friedman received options to purchase 35,000 shares of common stock. A recent analyst rating for

Tone
Negative 33/100
Event
Analyst action
Published
29 May 2026 01:09
Source
The Globe and Mail